Ko
Kojin Ther
San Diego CAFounded 202030 employees
Private CapbiotechPrivateOncology
Platform: T-cell Enrich
Market Cap
N/A
All Drugs
3
Clinical Trials
5
Failed / Terminated
0
FDA Approved
0
Drug Pipeline (3 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Sovazasiran | KOJ-1314 | Phase 3 | 2 | FcRn | NSCLC | ||
| Tezecapivasertib | KOJ-2414 | Phase 1/2 | 1 | KRASG12D | RettALL | ||
| Rimanaritide | KOJ-4250 | Phase 3 | 2 | CFTR | MesoMDS |
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (5)